Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Size, Share & Forecast Analysis 2025–2033

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Application (Hospital and Clinic, Retail Pharmacies, Other), by Types (Transthyretin Tetramer Stabilizer, RNA Interference, Antisense Oligonucleotides, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 138

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 138

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Overview

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market refers to the global industry focused on developing and marketing therapies for the treatment of hereditary transthyretin amyloid neuropathy, a rare and debilitating genetic disorder. As the growth outlook for this market continues to evolve, it is essential to understand the current Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size, which is estimated to be around $1.4 billion, and the market forecast, which anticipates significant expansion over the next few years. The scope of this market encompasses various therapies and treatments, including pharmacological interventions, gene therapies, and other innovative approaches.

Loading chart…

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market is expected to experience a significant growth rate, with a compound annual growth rate (CAGR) of around 20% over the forecast period. The primary drivers of this growth include increasing awareness of the disease, advances in technology, and a growing demand for effective treatments. Key forces shaping the industry include regulatory developments, competitive intensity, and supply-chain dynamics. The largest region for this market is currently North America, while the fastest-growing region is expected to be Asia-Pacific. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alnylam Pharmaceuticals; Akcea Therapeutics; AstraZeneca; Pfizer; Teva; Zydus Pharms; Avet Pharmaceuticals; Luoxin Pharmaceutical; Zhengzhou Taifeng Pharmaceutical; Shapuaisi Pharma; Tonghua Zhongsheng Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market is experiencing significant transformations driven by various factors. Understanding these dynamics is crucial for stakeholders to navigate the market effectively.

Growth Drivers2 items

Increasing awareness about Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) and its treatment options, leading to higher diagnosis rates and subsequently driving the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size.

Advancements in gene therapy and RNA-targeting therapies, offering new avenues for treatment and contributing to the growth forecast of the market.

Restraints2 items

High development costs and the lengthy process of bringing new treatments to market, which can hinder the growth forecast of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market.

Strict regulatory requirements and the need for extensive clinical trials, which can delay market entry and impact the overall Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America, where there is a growing demand for effective Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) treatments, presenting opportunities for market expansion and increasing the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size.

Collaborations and partnerships between pharmaceutical companies and research institutions, facilitating the development of innovative therapies and driving the growth forecast of the market.

Challenges2 items

Managing the high cost of treatments, which can limit patient access and affect the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market dynamics, particularly in regions with less comprehensive healthcare coverage.

Addressing the complexity of disease pathology, which requires a deep understanding of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) to develop effective treatments, posing a significant challenge to market players and impacting the growth forecast.

Market Segmentation

Loading chart…

The Application segment of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market refers to the various uses of therapies and treatments for the disease. This includes the treatment of neuropathic symptoms, such as pain, numbness, and weakness, as well as the management of other systemic symptoms. The Application segment is a crucial aspect of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) segmentation, as it helps to identify the specific areas where treatments are most needed.

The Types segment of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market is further divided into subtypes, including [object Object] and [object Object]. These subtypes represent different approaches to treating the disease, such as gene therapy, small molecule therapy, and immunotherapy. Understanding the Types segment is essential for developing effective treatment strategies and for identifying opportunities for growth in the market taxonomy of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market.

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segmentation Breakdown9 items

Application

Hospital and Clinic

Retail Pharmacies

Other

Types

Transthyretin Tetramer Stabilizer

RNA Interference

Antisense Oligonucleotides

Other

Regional Insights

Loading chart…

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of novel therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America - established ecosystem maturity, high demographics awareness, and significant investments in research and development; Europe - regulatory support, increasing adoption of novel therapies, and growing infrastructure; Asia Pacific - large demographics base, increasing adoption of digital health technologies, and government initiatives to improve healthcare access; Latin America - growing infrastructure, increasing adoption of generic therapies, and partnerships between local and international pharmaceutical companies; Middle East & Africa - government investments in healthcare infrastructure, increasing adoption of digital health technologies, and growing awareness of rare diseases.

The regional forecast indicates that the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market will experience significant growth in the Asia Pacific region, driven by emerging markets and increasing demand for novel therapies. In contrast, the Middle East & Africa region is expected to experience relatively slower growth due to limited infrastructure and regulatory challenges.

Competitive Landscape

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) competitive landscape is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is characterized by high competition, with companies focusing on differentiation through innovative products and strong distribution networks.

Companies in the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market employ various strategies to stay competitive, including M&A, partnerships, product launches, and R&D. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To differentiate themselves, companies focus on technology, service models, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Alnylam Pharmaceuticals: innovation pipeline

Akcea Therapeutics: regional expansion

AstraZeneca: premium pricing

Pfizer: OEM tie-ups

Teva: local manufacturing

Zydus Pharms: vertical integration

Key Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Companies11 items

Alnylam Pharmaceuticals

Akcea Therapeutics

AstraZeneca

Pfizer

Teva

Zydus Pharms

Avet Pharmaceuticals

Luoxin Pharmaceutical

Zhengzhou Taifeng Pharmaceutical

Shapuaisi Pharma

Tonghua Zhongsheng Pharmaceutical

Market Ecosystem

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. The ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where these inputs are integrated into treatments; and downstream, where finished products are distributed to end users. Value is created and captured at each stage, with technology providers, manufacturers, and distributors playing critical roles in the value chain analysis.

Raw material/component suppliers — provide active pharmaceutical ingredients

Technology providers — develop novel therapeutic approaches

OEMs / manufacturers — produce finished pharmaceutical products

Distributors / channel partners — deliver products to healthcare providers

Service providers / after-sales — offer patient support and monitoring services

Regulators/standards bodies — oversee safety and efficacy of treatments

End users / buyers — healthcare providers and patients

The flow of value within the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) ecosystem is influenced by various control points, including regulatory approvals and reimbursement decisions. Dependency risks, such as input constraints and standards compliance, can impact the availability and affordability of treatments. Switching costs, partnerships, and interoperability requirements may also affect the dynamics of the ecosystem, which can differ by region due to varying regulatory frameworks, healthcare systems, and patient needs.

Recent Industry Insights

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships have been forged to enhance research and development of novel therapies, while mergers and acquisitions have led to increased consolidation in the market. Notably, there have been several product launches, including gene therapies and small molecule inhibitors, which have expanded treatment options for patients. Furthermore, regulatory changes have facilitated faster approval of new therapies, and shifts in consumer trends have emphasized the need for more targeted and personalized treatments.

Additionally, the market has seen notable funding rounds and expansions, with major pharmaceutical companies investing heavily in the development of new treatments for ATTRv-PN. These advancements are expected to drive growth in the market, with the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) industry poised for significant expansion in the coming years. As research continues to uncover the complexities of ATTRv-PN, the market is likely to evolve, with emerging trends and technologies shaping the future of the industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market outlook. The market attractiveness is moderate, driven by the growing prevalence of ATTRv-PN and the increasing awareness among healthcare professionals. Competitive intensity is high, with several pharmaceutical companies investing in research and development of new therapies. The long-term outlook is positive, with the market expected to grow significantly over the next decade.

The innovation landscape is rapidly evolving, with ongoing clinical trials and the emergence of novel therapies. However, the demand–supply balance is a concern, as the limited availability of effective treatments may hinder market growth. Key risk factors include the high development costs of new therapies, regulatory challenges, and the potential for patent expirations. Overall, the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market requires careful navigation and strategic decision-making to capitalize on emerging opportunities.

12 items

1. Executive Summary

2. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Competition by Key Manufacturers

9.1. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN): Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Alnylam Pharmaceuticals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Akcea Therapeutics

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. AstraZeneca

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Pfizer

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Teva

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Zydus Pharms

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Avet Pharmaceuticals

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Luoxin Pharmaceutical

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Zhengzhou Taifeng Pharmaceutical

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Shapuaisi Pharma

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Tonghua Zhongsheng Pharmaceutical

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market

Figure 4: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market: Drivers

Figure 5: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market: Challenges

Figure 6: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market: Trends

Figure 7: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market: Opportunity

Figure 8: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market: Restraint

Figure 9: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Value (USD Million) By Region

Figure 19: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Value (USD Million) By Region

Figure 27: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By: Regions (2032)

Figure 28: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Volume (K) By Region

Figure 29: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Value (USD Million) By Region

Figure 37: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By: Regions (2032)

Figure 38: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Volume (K) By Region

Figure 39: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

117 items

Table 1: Market Segmentation Analysis

Table 2: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Value (USD Million) By Region

Table 14: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Volume (K) By Region

Table 31: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 52: Alnylam Pharmaceuticals. Products Portfolio

Table 53: Akcea Therapeutics Basic Information And Sales Area

Table 54: Akcea Therapeutics. Products Portfolio

Table 55: AstraZeneca Basic Information And Sales Area

Table 56: AstraZeneca. Products Portfolio

Table 57: Pfizer Basic Information And Sales Area

Table 58: Pfizer. Products Portfolio

Table 59: Teva Basic Information And Sales Area

Table 60: Teva. Products Portfolio

Table 61: Zydus Pharms Basic Information And Sales Area

Table 62: Zydus Pharms. Products Portfolio

Table 63: Avet Pharmaceuticals Basic Information And Sales Area

Table 64: Avet Pharmaceuticals. Products Portfolio

Table 65: Luoxin Pharmaceutical Basic Information And Sales Area

Table 66: Luoxin Pharmaceutical. Products Portfolio

Table 67: Zhengzhou Taifeng Pharmaceutical Basic Information And Sales Area

Table 68: Zhengzhou Taifeng Pharmaceutical. Products Portfolio

Table 69: Shapuaisi Pharma Basic Information And Sales Area

Table 70: Shapuaisi Pharma. Products Portfolio

Table 71: Tonghua Zhongsheng Pharmaceutical Basic Information And Sales Area

Table 72: Tonghua Zhongsheng Pharmaceutical. Products Portfolio

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Value (USD Million) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Volume (K) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Value (USD Million) By Region

Table 82: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By Region (2025-2032)

Table 83: North America Market Value (USD Million) (2025-2032) By Country

Table 84: North America Market Value (USD Million) (2025-2032) By Application

Table 85: North America Market Value (USD Million) (2025-2032) By Types

Table 86: Europe Market Value (USD Million) (2025-2032) By Country

Table 87: Europe Market Value (USD Million) (2025-2032) By Application

Table 88: Europe Market Value (USD Million) (2025-2032) By Types

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 92: South America Market Value (USD Million) (2025-2032) By Country

Table 93: South America Market Value (USD Million) (2025-2032) By Application

Table 94: South America Market Value (USD Million) (2025-2032) By Types

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 98: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Volume (K) By Region

Table 99: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share (%) By Region (2025-2032)

Table 100: North America Market Volume (K) (2025-2032) By Country

Table 101: North America Market Volume (K) (2025-2032) By Application

Table 102: North America Market Volume (K) (2025-2032) By Types

Table 103: Europe Market Volume (K) (2025-2032) By Country

Table 104: Europe Market Volume (K) (2025-2032) By Application

Table 105: Europe Market Volume (K) (2025-2032) By Types

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 107: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 109: South America Market Volume (K) (2025-2032) By Country

Table 110: South America Market Volume (K) (2025-2032) By Application

Table 111: South America Market Volume (K) (2025-2032) By Types

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 113: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 115: Research Programs/Design For This Report

Table 116: Key Data Information From Secondary Sources

Table 117: Key Data Information From Primary Sources

FAQs

1. What is the current Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size?

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size is approximately USD 1.2 billion as of 2023.

2. What is the expected growth forecast for the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

3. What are the key drivers of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

Key drivers include rising awareness and advancements in treatments, fueling the future outlook.

4. What are the major challenges faced by the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

Challenges include high treatment costs and limited availability of effective therapies, hindering growth.

5. Which regions are expected to lead the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

North America and Europe are expected to dominate the market due to high awareness and healthcare infrastructure.

6. Who are the top companies in the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

Top companies include Pfizer, Alnylam Pharmaceuticals, and Akcea Therapeutics, driving innovation and growth.

7. What future opportunities exist in the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

Emerging opportunities include gene therapies and novel medications, offering promising future outlook.

8. How will technology impact the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

Advances in technology will improve diagnosis and treatment, driving growth and innovation in the market.

9. What is the current regulatory landscape for the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

The regulatory landscape is evolving, with increasing focus on approving effective and safe treatments, shaping the market.

10. What is the expected impact of regulatory changes on the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

Regulatory changes will likely drive growth, as new treatments are approved and access to therapies expands, improving patient outcomes.

Contact for Full Report

Loading report content...

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Size, Share & Forecast Analysis 2025–2033

Market Snapshot

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segmentation

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size?

2. What is the expected growth forecast for the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

3. What are the key drivers of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

4. What are the major challenges faced by the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

5. Which regions are expected to lead the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

6. Who are the top companies in the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

7. What future opportunities exist in the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

8. How will technology impact the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

9. What is the current regulatory landscape for the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

10. What is the expected impact of regulatory changes on the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segmentation

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size?

2. What is the expected growth forecast for the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

3. What are the key drivers of the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

4. What are the major challenges faced by the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

5. Which regions are expected to lead the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

6. Who are the top companies in the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

7. What future opportunities exist in the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

8. How will technology impact the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

9. What is the current regulatory landscape for the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

10. What is the expected impact of regulatory changes on the Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation